AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 274.55B |
| Revenue (ttm) | 50.03B |
| Net Income (ttm) | 8.71B |
| Shares Out | n/a |
| EPS (ttm) | 5.57 |
| PE Ratio | 31.53 |
| Forward PE | 20.30 |
| Dividend | 2.71 (1.69%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 14,221 |
| Average Volume | 10,876 |
| Open | 158.90 |
| Previous Close | 159.75 |
| Day's Range | 157.90 - 161.20 |
| 52-Week Range | 111.00 - 166.30 |
| Beta | 0.19 |
| RSI | 53.92 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
If You Invested $100 In AstraZeneca Stock 5 Years Ago, You Would Have This Much Today
AstraZeneca (NYSE: AZN) has outperformed the market over the past 5 years by 4.19% on an annualized basis producing an average annual return of 16.3%. Currently, AstraZeneca has a market capitalizati...
Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but m...
AstraZeneca Prices $2 Bln Three Tranche Bond Offering
(RTTNews) - AstraZeneca PLC (AZN, AZN.L), a Swedish-British pharmaceutical and biotechnology company, on Thursday priced a three-tranche bond offering totalling $2 billion through its wholly owned sub...
AstraZeneca Launches “A.Catalyst Thailand Hub”: AI-Integrated Health Transformation
AstraZeneca (Thailand) Ltd., in collaboration with the public and private sectors, academia, and patient networks, has officially launched the A.Catalyst Network Thailand Hub. This global health innov...
The £168MILLION man: That's how much AstraZeneca boss Pascal Soriot has been paid in 14 years at the top
Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma giant to £168million.
AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025
The drug maker’s annual report showed his total pay lifted 6.4% last year after he was awarded nearly £16 million in bonuses and share awards.
AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025
AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-paid executives, a fil...
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AIM) ("AIM" or the "Company") today announced milestones in the expected timeline for the ongoing Phase 2 clinical study eval...
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s (NYSE: ABBV) combination treatment for chronic lymphocytic leukemia (CLL). The FDA has approved the combination of Vencle...
AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment
AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment
CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
AstraZeneca’s CALQUENCE (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lympho...
AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment
AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment
FDA Approves AstraZeneca's Calquence Plus Venetoclax For Chronic Lymphocytic Leukemia
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) on Friday said the US Food and Drug Administration (FDA) has approved its Calquence in combination with venetoclax for the treatment of adults with chronic...
AstraZeneca (AZN) Strikes Major Licensing Deal in China
AstraZeneca (AZN) Strikes Major Licensing Deal in China
EMA Validates Enhertu Application for AstraZeneca (AZN)
EMA Validates Enhertu Application for AstraZeneca (AZN)
Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca'...
FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)
FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)
FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals
FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals
AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development
AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development
AstraZeneca, Bristol partner with Evinova to use AI in drug development
Top 3 Health Care Stocks That May Collapse This Quarter
As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Apple, Ulta Beauty, AstraZeneca And A Real Estate Stock On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Joshua Brown , co-founder and CEO of Ritholtz Wealth Management, said he remains long on Apple Inc. (NASDAQ: AAPL). Supporting his view, Wedbush analyst Da...
Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors
Impax International Sustainable Economy Fund portfolio marginally underperformed MSCI EAFE benchmark, driven primarily by stock-specific effects and style tilts. AstraZeneca's stock has an attractive ...
Final Trades: Apple, AstraZeneca, Vici Properties and Ulta Beauty
The Investment Committee give you their top stocks to watch for the second half.